Eterna Therapeutics
ERNA
11 hedge funds and large institutions have $1.19M invested in Eterna Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 22 closing their positions.
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
51% less capital invested
Capital invested by funds: $2.44M → $1.19M (-$1.25M)
65% less funds holding
Funds holding: 31 → 11 (-20)
86% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPWM
Cypress Point Wealth Management
Dallas,
Texas
|
+$355K |
| 2 |
NW
Naviter Wealth
Little Rock,
Arkansas
|
+$299K |
| 3 |
AWS
AJ Wealth Strategies
New York
|
+$128K |
| 4 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$28.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSAG
Lake Street Advisors Group
Portsmouth,
New Hampshire
|
-$604K |
| 2 |
AC
Armistice Capital
New York
|
-$274K |
| 3 |
Renaissance Technologies
New York
|
-$209K |
| 4 |
Millennium Management
New York
|
-$207K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$56.4K |
ERNA Hedge Fund Activity: Q4 2022 in Review
11 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q4 2022, worth a combined $1.19M — down 51% from $2.44M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ERNA and 3 opened new positions — a net loss of 19 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Cypress Point Wealth Management, opening a new position worth an estimated $355K. The largest seller was Lake Street Advisors Group, exiting entirely with an estimated $604K sold.
- 11 institutional investors held Eterna Therapeutics (ERNA) as of Q4 2022, down from 31 in Q3 2022.
- Funds reported $1.19M of Eterna Therapeutics stock for Q4 2022, down 51% quarter-over-quarter.
- 3 funds opened new Eterna Therapeutics positions in Q4 2022 and 22 closed out, a net change of -19 holders.
- The largest Eterna Therapeutics buyer in Q4 2022 was Cypress Point Wealth Management, an estimated $355K added.
- The largest Eterna Therapeutics seller in Q4 2022 was Lake Street Advisors Group, an estimated $604K sold.
Based on aggregated 13F filings for Q4 2022.